We are live on
!
Find out more
CM
Crestline Management Portfolio holdings
AUM
$46.3M
1-Year Est. Return
48.82%
This Fund
S&P 500
This Quarter
Est. Return
+31.44%
1 Year Est. Return
+48.82%
3 Year Est. Return
+52.52%
5 Year Est. Return
+37.91%
10 Year Est. Return
+316.44%
AUM
$719M
AUM Growth
-$27.1M
(-3.6%)
Cap. Flow
-$214M
Cap. Flow
% of AUM
-29.71%
Top 10 Holdings %
Top 10 Hldgs %
66.29%
Holding
201
New
72
Increased
18
Reduced
27
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Travelers Companies
TRV
|
+$7.93M |
| 2 |
FNB Corp
FNB
|
+$7.61M |
| 3 |
Sherwin-Williams
SHW
|
+$7.06M |
| 4 |
Allstate
ALL
|
+$5.58M |
| 5 |
Willis Towers Watson
WTW
|
+$5.57M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$274M |
| 2 |
Celanese
CE
|
+$6.41M |
| 3 |
MON
Monsanto Co
MON
|
+$6.27M |
| 4 |
Bunge Global
BG
|
+$5.97M |
| 5 |
Air Products & Chemicals
APD
|
+$4.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.98% |
| 2 | Industrials | 5.93% |
| 3 | Healthcare | 5.67% |
| 4 | Technology | 4.78% |
| 5 | Communication Services | 1.69% |
Similar funds
MCMC
RRC
PCM
NPCM
FCM
EGI
IPHI
SM
Crestline Management's Q3 2017 Portfolio in Review
As of Q3 2017, Crestline Management held 201 positions worth $719M, down 3.6% from $746M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Crestline Management withdrew a net $214M in Q3 2017, closing 81 positions and reducing 27 holdings. Its most notable exit was Celanese, an estimated $6.41M position sold in full.
By sector, the portfolio is most concentrated in Financials at 20% of assets, up from 13% a quarter earlier, followed by Industrials and Healthcare.
Against the trend, Crestline Management opened a new position in Travelers Companies worth $7.78M.
- Crestline Management's largest Q3 2017 buy was Travelers Companies: 63,503 shares worth $7.78M.
- Crestline Management added most to FNB Corp in Q3 2017, an estimated $7.61M increase.
- Crestline Management's biggest Q3 2017 reduction was Juno Therapeutics, Inc., cutting an estimated $274M.
- Crestline Management fully exited Celanese in Q3 2017, selling an estimated $6.41M.
- Crestline Management's ten largest holdings make up 66% of its $719M portfolio in Q3 2017.
- Crestline Management opened 72 new positions and closed 81 in Q3 2017.
- Crestline Management's portfolio value fell 3.6% quarter-over-quarter to $719M.
Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.